Moderna Inc. today announced that its mRNA-1273 vaccine candidate against COVID-19 is 94.5% effective, according to early data.

The candidate is currently subject to a phase 3 clinical trial, with 30,000 U.S. participants enrolled, including those at high risk of severe COVID-19 complications.

The Moderna announcement follows similar claims of effectiveness by a vaccine candidate developed by Pfizer and BioNTech, with a prominent difference between the two vaccines; while the Pfizer candidate must be stored at minus 80 degrees Celsius, Moderna’s is stable between 2 and 8 degrees Celsius — the temperature of standard refrigerators — for up to 30 days.

Moderna expects to produce approximately 20 million doses of its vaccine by the end of 2020, with an additional 500 million to 1 billion doses worldwide in 2021. Of this stock, the U.S. has already purchased 100 million doses, pending Food and Drug Administration approval.

Related News Articles

Headline
In a statement (LINK to come) submitted to the Senate Finance Committee for a hearing today on COVID-19 health care flexibilities, AHA urged Congress and…
Headline
The National Academy of Medicine yesterday released separate discussion papers examining the experiences of payers and clinicians during the COVID-19 pandemic…
Headline
COVID-19 vaccination coverage was about 7 percentage points lower in rural counties than in urban counties as of April 10, the Centers for Disease Control and…
Headline
The Federal Emergency Management Agency yesterday released guidance to help emergency managers plan for disaster response and recovery while adhering to…
Headline
Building integrated systems of care can lead to meaningful benefits for patients and help hospitals best serve the health needs of their communities, writes…
Headline
The Food and Drug Administration Friday updated its emergency use authorizations for two intravenous infusion therapies for outpatients at risk for progressing…